Pacific Edge Limited (ASX:PEB)

Market Cap	75.05M
Revenue (ttm)	20.76M
Net Income (ttm)	-26.42M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,649
Average Volume	55,587
Open	0.1050
Previous Close	0.0750
Day's Range	0.0750 - 0.1050
52-Week Range	0.0500 - 0.1800
Beta	1.03
RSI	30.83
Earnings Date	May 23, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PEB

Financial Performance

In 2023, Pacific Edge's revenue was 25.23 million, an increase of 19.95% compared to the previous year's 21.03 million. Losses were -29.54 million, 9.53% more than in 2022.

Financial numbers in NZD